Symbols

IBO

Impact BioMedical·AMEX

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IBO

Impact Biomedical Inc.

A pharmaceutical research and biomedical intellectual property company

Industry

Pharmaceutical

Established Date

10/16/2018

Listing Date

09/16/2024

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.impactbiomedinc.com

Security Type

Common stock

Office address

1400 Broadfield Blvd., Suite 130, Houston, TX 77084

Business

Introduction

Impact BioMedical Inc., a Nevada corporation, was founded on October 16, 2018. The company is a subsidiary of DSS, Inc. The company is committed to discovering, validating and patenting unique science and technology, and jointly developing new products in the field of human health with external partners through licensing, cooperative development, joint ventures and other partnerships.

Company Financials

EPS

IBO has released its 2025 Q2 earnings. EPS was reported at -1.18, versus the expected 0, missing expectations. The chart below visualizes how IBO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IBO has released its 2025 Q4 earnings report, with revenue of 7.00K, reflecting a YoY change of NaN%, and net profit of 5.24M, showing a YoY change of 119.29%. The Sankey diagram below clearly presents IBO's revenue sources and cost distribution.